Excerpt of SEC Filnig by Amgen, Inc.
THOUSAND OAKS, Calif., March 1, 2007 - Below is an excerpt from an SEC filing by Amgen, Inc. that says the company received an informal inquiry from the SEC's regarding a study of the drug Aranesp. The full filing is attached."On February 19, 2007, Amgen received an informal inquiry from the SEC’s Atlanta District Office regarding the Danish Head and Neck Cancer (DAHANCA) 10 study (the “Study”). The SEC’s Atlanta District Office has requested that Amgen voluntarily provide certain information and documentation related to the Study. We intend to fully cooperate with the request."
Clinical Trial Results Archive
2008: Jan | Feb | Mar | Apr | May
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Dec






